ARDX

Ardelyx

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/07/26

Business Summary

Dow operates as a large-scale chemicals manufacturer producing commodity and specialty chemical products used across packaging, infrastructure, and consumer applications. Its cash generation historically depends on feedstock cost spreads, scale efficiencies, and global production footprint optimization. The moat is rooted in asset intensity, supply chain integration, and long-term industrial customer relationships rather than intellectual property. When chemical pricing and demand cycles turn favorable, fixed-cost absorption can drive powerful cash flow expansion — but when spreads compress, profitability erodes quickly, as current margins demonstrate.

VALUATION

P/E

-

Market Cap ($M USD)

$1,515

Forward P/E

11.8

PEG

-

PRICE TO SALES

3.7

PRICE TO BOOK

9.1

EV / EBITDA

-50

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.26

Next Year EPS Growth Estimate

$0.52

Next Year Revenue Growth Estimate

34.40%

Return on Equity (ROE)

-36.90%

Operating Margin

-10.10%

Debt-to-Equity

1.3

Piotroski F-Score

4

Altman Z-Score

1.3

Return on Invested Capital (ROIC)

-11.20%%

Current Ratio

4.3

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is not a growth story — it’s a stressed balance sheet hiding behind a low Price/Sales of 0.7 and a modest Price/Book of 1.8. A Forward P/E of 31.7 against a projected EPS Next Year (Est.) of -$3.70 signals that forward earnings visibility is either distorted or collapsing, and the Altman Z-Score of 1.7 places the company firmly in financial distress territory. Operating Margin of -16.40% and ROIC of -5.50% confirm capital destruction, not value creation. The market is not mispricing growth — it is pricing fragility. This is a cyclical chemicals operator with weak profitability metrics and elevated solvency risk.

AI Exposure / Tech Reliance

As a Chemicals company in the Basic Materials sector, Dow’s AI exposure is indirect and demand-driven rather than platform-driven. AI infrastructure expansion could increase demand for specialty materials and industrial inputs, but there is no evidence in the numbers of superior profitability or reinvestment capacity to capitalize on that trend. With Operating Margin at -16.40%, the company lacks current operating leverage to aggressively fund tech adaptation.

The Bull Case

A value investor could argue that a Market Cap of $28,072M paired with a Price/Sales of 0.7 reflects deep cyclical pessimism. Return on Equity of 2.50% is low but positive, and a Current Ratio of 2 suggests adequate short-term liquidity despite operating pressure. Debt / Equity at 0.40% is conservative, implying the balance sheet is not heavily levered relative to equity, which provides optionality if margins normalize. The Forward PEG of 1.3 suggests growth is not outrageously priced if earnings stabilize, and institutional participation at 36.94% indicates the name is not abandoned by professional capital. In a sharp chemicals cycle recovery, operating leverage could dramatically swing results given how depressed margins currently are.

The Bear Case

The bear case is far more straightforward: Operating Margin of -16.40%, ROIC of -5.50%, and a Piotroski F-Score of 3 signal fundamental deterioration. An Altman Z-Score of 1.7 places the firm in the distress zone, and projected EPS of -$3.70 next year against a Forward P/E of 31.7 suggests earnings compression or unreliable forward metrics. Short % of Float at -12.90% reflects elevated bearish positioning, reinforcing skepticism around near-term recovery. Add in a Consensus Rating of 3.70% with a Mean Consensus Target Price of 2.26, and the setup reflects weak confidence, fragile profitability, and limited margin for execution error.

Market Sentiment & Smart Money

Short Interest %

10.00%

Analyst Consensus

1.17

Average Analyst Price Target

$16.10

Institutional Ownership %

69.60%

1-Year Beta

0.92

Insider Buying % (6 Mo)

2.90%%

Distance to 52-Week High

73.60%%

Distance to 52-Week Low

192.50%%